Overview
Interstitial pneumonia encompasses a spectrum of lung diseases characterized by inflammation and fibrosis in the lung interstitium. Acute exacerbations pose significant diagnostic and therapeutic challenges due to limited understanding of their pathophysiology 1.Diagnosis
Pathologic Exam: Crucial for definitive diagnosis, especially in acute exacerbations, though its specific role remains under investigation 1.
High-Resolution CT (HRCT): Essential for distinguishing between idiopathic interstitial pneumonias (IIPs) based on radiological features 2.
Multidisciplinary Approach: Recommended for accurate diagnosis, combining radiological, pathological, and clinical findings 2.
Biopsy and Bronchoalveolar Lavage (BAL): Useful in specific cases like lymphocytic interstitial pneumonia for diagnosis and monitoring 7.Management
Desquamative Interstitial Pneumonitis (DIP): Chloroquine (10 mg/kg/day) can lead to clinical improvement 5.
Surgical Intervention: Considered for lymphocytic interstitial lung disease with refractory symptoms, showing potential benefit 3.
Monitoring: Patients in remission, particularly those with DIP, require indefinite follow-up due to potential late relapse 4.
Medication Withdrawal: Effective in reversing diphenylhydantoin-induced lymphocytic interstitial pneumonia 7.Special Populations
Pediatrics: Chloroquine treatment can be effective in infants with desquamative interstitial pneumonia 5.
Comorbidities: Lymphoid interstitial pneumonia can coexist with chronic active hepatitis and renal tubular acidosis, necessitating comprehensive management 10.Key Recommendations
Utilize multidisciplinary meetings for diagnosis of idiopathic interstitial pneumonias to integrate radiological, pathological, and clinical data (Evidence: Moderate 2).
Consider indefinite follow-up for patients with desquamative interstitial pneumonia in remission due to potential late relapse (Evidence: Weak 4).
Evaluate the role of specific immunosuppressive therapies, such as chloroquine, in treating desquamative interstitial pneumonia (Evidence: Weak 5).
Monitor patients with suspected drug-induced interstitial lung diseases closely, with consideration for medication withdrawal if indicated (Evidence: Weak 7).References
1 Mlika M, Berraies A, Hamzaoui A, Mezni F. The role of the pathologic exam in the acute exacerbations of the interstitial pneumonia. La Tunisie medicale 2017. link
2 Dixon S, Benamore R. The idiopathic interstitial pneumonias: understanding key radiological features. Clinical radiology 2010. link
3 Gupta SK. Lymphocytic interstitial lung disorder: an isolated entity. The Journal of the Association of Physicians of India 2002. link
4 Lipworth B, Woodcock A, Addis B, Turner-Warwick M. Late relapse of desquamative interstitial pneumonia. The American review of respiratory disease 1987. link
5 Springer C, Maayan C, Katzir Z, Ariel I, Godfrey S. Chloroquine treatment in desquamative interstitial pneumonia. Archives of disease in childhood 1987. link
6 Majeski JA, Stinnett JD, Cameron DJ. Suppressor T cell activity in lymphoid interstitial pneumonia. Journal of surgical oncology 1987. link
7 Chamberlain DW, Hyland RH, Ross DJ. Diphenylhydantoin-induced lymphocytic interstitial pneumonia. Chest 1986. link
8 Robinson WF, Ellis TM. The pathological features of an interstitial pneumonia of goats. Journal of comparative pathology 1984. link90008-2)
9 Galbenu P. Lymphoid interstitial pneumonia. Morphologie et embryologie 1980. link
10 Helman CA, Keeton GR, Benatar SR. Lymphoid interstitial pneumonia with associated chronic active hepatitis and renal tubular acidosis. The American review of respiratory disease 1977. link